Gene silencing shows promise for treating two fatal neurological disorders

A drug, engineered to combat the gene that causes spinocerebellar ataxia type 2 (SCA2), might also be used to treat amyotrophic lateral sclerosis (ALS), researchers have demonstrated in two studies of mice.